Education
About Us
Working with TipRanks
Follow Us
Beta Bionics, Inc. (BBNX)
NASDAQ:BBNX
Earnings Data
Report Date
May 12, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.49Last Year’s EPS
-0.93Same Quarter Last Year
Moderate Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a strong operational and commercial performance in 2025 — marked by substantial revenue growth (+54% YoY), accelerating user adoption (≈20,000 new users), improving gross margins (Q4 59%) and meaningful pipeline progress (Mint and bihormonal milestones). The company is well-capitalized ($265M) and has broadened PBM/pharmacy coverage. Key negatives include a recent FDA warning letter tied to quality systems and MDR timing (remediation in progress), materially higher operating expenses (+42% YoY in Q4), and short-term margin and seasonality headwinds related to pharmacy mix and Q1 cadence. Management reiterated confidence in remediation timelines and in their 2026 guidance, while opting for a deliberate sales force ramp and slightly reduced public granularity on new patient starts.Company Guidance
Strong Revenue Growth
Full year 2025 net sales of $100.3M, up 54% year-over-year; Q4 2025 net sales $32.1M, up 57% year-over-year.
Significant User Adoption and Installed Base Expansion
Close to 20,000 new users adopted iLet in 2025, more than doubling the installed base entering the year; total installed base ≈35,000 users since launch.
Robust New Patient Starts
Q4 new patient starts of 5,592, up 37% year-over-year and +5% sequentially; FY 2025 new starts mix included a high share from pharmacy.
Improving Gross Margin and Scale Benefits
FY 2025 gross margin 55.4% (expanded slightly YoY); Q4 gross margin 59%, up 179 basis points YoY, driven by scale, manufacturing leverage and growing high-margin pharmacy recurring revenue.
Pharmacy Channel Expansion and PBM Coverage
Percentage of new patient starts through pharmacy rose to the high 20s% for FY2025 (from high single-digits prior year); Q4 had a low-30s% pharmacy mix for new starts. Company has formulary agreements with all major PBMs and ~80% of lives covered.
Recurring Revenue and Retention
Pharmacy-installed base generates high-margin recurring revenue (management cited ~ $450/month ARR per pharmacy user) and strong patient retention in both DME and pharmacy channels.
Healthy Balance Sheet
Cash, cash equivalents and short/long-term investments of approximately $265M as of Dec 31, 2025; company states it is sufficiently capitalized to fund initiatives and expects to generate free cash flow ahead of peers.
Progress on Pipeline and Product Roadmap
Mint patch-pump program tracking toward unconstrained commercial launch by end of 2027; completed first-in-human feasibility trial of bihormonal system (no safety signals for glucagon); completed PK/PD trial for glucagon asset; planning further Phase IIa then Phase IIb leading to pivotal trials.
BBNX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BBNX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 17, 2026 | $13.97 | $13.61 | -2.58% |
Oct 28, 2025 | $24.28 | $26.79 | +10.34% |
Jul 29, 2025 | $14.66 | $16.76 | +14.32% |
May 06, 2025 | $11.35 | $14.37 | +26.61% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Beta Bionics, Inc. (BBNX) report earnings?
Beta Bionics, Inc. (BBNX) is schdueled to report earning on May 12, 2026, After Close (Confirmed).
What is Beta Bionics, Inc. (BBNX) earnings time?
Beta Bionics, Inc. (BBNX) earnings time is at May 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BBNX EPS forecast?
BBNX EPS forecast for the fiscal quarter 2026 (Q1) is -0.49.